(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
3 March 2005 (03.03.2005)

PCT

(10) International Publication Number
WO 2005/019194 A1

(51) International Patent Classification[7]: C07D 295/16, 217/06, 213/74, 211/16, 317/58, 213/36, 239/42, 251/46, 211/58, 265/30, A61K 31/40, 31/445, 31/472, 31/496, 31/5375

(21) International Application Number:
PCT/GB2004/003558

(22) International Filing Date: 18 August 2004 (18.08.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

0319917.1	23 August 2003 (23.08.2003)	GB
0328632.5	10 December 2003 (10.12.2003)	GB

(71) Applicants *(for all designated States except US)*: **VERNALIS (OXFORD) LIMITED** [GB/GB]; Granta Park, Abington, Cambridge CB1 6GB (GB). **LABORATOIRES SERONO S.A.** [CH/CH]; Z.I. de l'Ouriettaz, CH-1170 Aubonne (CH).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **PAIN, Gilles** [FR/IT]; Newron Pharmaceuticals SpA, Via Ludovico Ariosto 21, I-20091 Bresso (IT). **DAVIES, Stephen, John** [GB/GB]; Chroma Therapeutics Limited, 92 Milton Park, Abindon, Oxfordshire OX14 4RY (GB). **BOMBRUN, Agnes** [FR/FR]; 1153 Route du Saleve, F-74560 Monnetier-Mornex (FR).

(74) Agent: **WALLS, Alan, James**; Vernalis (Oxford) Limited, Granta Park, Abington, Cambridge CB1 6GB (GB).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: DERIVATIVES OF HYDROXAMIC ACID AS METALLOPROTEINASE INHIBITORS



(I)

(II)

(57) Abstract: Compounds of formula (I) are inhibitors of matrix metalloproteinases, and are of use in the treatment of, for example fibrotic disease, multiple sclerosis, emphysemia, bronchitis and asthma: formula (I) wherein Ar represents an optionally substituted aryl, heteroaryl, C_3-C_8 cycloalkyl or heterocycloakyl group; R represents hydrogen or C_1-C_6 alkyl, or C_3-C_6 cycloalkyl; Alk represents a divalent C_1-C_5 alkylene or C_2-C_5 alkenylene radical; and R_1 and R_2 taken together with the nitrogen atom to which they are attached form a first heterocycloalkyl ring which is optionally fused to a second C_3-C_8 cycloalkyl or heterocycloalkyl ring, the said first and second rings being optionally substituted by at least one group of formula (II): formula (II) wherein m, p and n are independently 0 or 1; Z represents, hydrogen, or an optionally substituted carbocyclic or heterocyclic ring of from 5 to 7 ring atoms which is optionally fused to another optionally substituted carbocyclic or heterocyclic ring of from 5 to 7 ring atoms; Alk^1 and Alk^2 independently represent optionally substituted divalent C_1-C_3 alkylene radicals; X represents -0-, -S-, -S(O)-, $-S(O_2)$-, -C(=O)-, -NH-, $-NR_3$-, $-S(O_2)NH$-, $-S(O_2)NR_3$-, $-NHS(O_2)$-, or $-NR_3S(O_2)$-, where R_3 is C_1-C_3 alkyl.

WO 2005/019194 A1